Literature DB >> 1531817

Optimal dose regimen for paroxetine.

D L Dunner1, G C Dunbar.   

Abstract

The dose regimen for paroxetine in the treatment of depression has been well established through a number of individual dosing studies and analyses from the worldwide clinical data base. The starting dose, which is also the minimal effective dose, is 20 mg/day. For most patients, 20 mg/day will also be the optimal dose. For patients who do not show an adequate therapeutic response within 1 to 3 weeks of initiating therapy, the dose of paroxetine should be increased in 10-mg increments no more often than at weekly intervals to a maximum of 50 mg/day. Medication should be given as a single daily dose, usually in the morning. The therapeutic dose range in the elderly is 20 mg to 40 mg of paroxetine.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1531817

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  18 in total

Review 1.  Therapeutic drug monitoring of antidepressants: cost implications and relevance to clinical practice.

Authors:  M J Burke; S H Preskorn
Journal:  Clin Pharmacokinet       Date:  1999-08       Impact factor: 6.447

Review 2.  A risk-benefit assessment of pharmacotherapies for clinical depression in children and adolescents.

Authors:  J Renaud; D Axelson; B Birmaher
Journal:  Drug Saf       Date:  1999-01       Impact factor: 5.606

Review 3.  Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders.

Authors:  N S Gunasekara; S Noble; P Benfield
Journal:  Drugs       Date:  1998-01       Impact factor: 9.546

4.  Paroxetine exposure skews litter sex ratios in mice suggesting a Trivers-Willard process.

Authors:  Shannon Marie Gaukler; James Steven Ruff; Wayne K Potts
Journal:  Behav Ecol       Date:  2016-02-27       Impact factor: 2.671

Review 5.  Paroxetine. A pharmacoeconomic evaluation of its use in depression.

Authors:  M I Wilde; R Whittington
Journal:  Pharmacoeconomics       Date:  1995-07       Impact factor: 4.981

Review 6.  Sertraline. A pharmacoeconomic evaluation of its use in depression.

Authors:  R Davis; M I Wilde
Journal:  Pharmacoeconomics       Date:  1996-10       Impact factor: 4.981

Review 7.  Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.

Authors:  S H Preskorn
Journal:  Clin Pharmacokinet       Date:  1997       Impact factor: 6.447

8.  Low-dose paroxetine exposure causes lifetime declines in male mouse body weight, reproduction and competitive ability as measured by the novel organismal performance assay.

Authors:  Shannon M Gaukler; James S Ruff; Tessa Galland; Kirstie A Kandaris; Tristan K Underwood; Nicole M Liu; Elizabeth L Young; Linda C Morrison; Garold S Yost; Wayne K Potts
Journal:  Neurotoxicol Teratol       Date:  2014-11-12       Impact factor: 3.763

Review 9.  Severe depression: is there a best approach?

Authors:  S B Sonawalla; M Fava
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 10.  The effect of increased serotonergic neurotransmission on aggression: a critical meta-analytical review of preclinical studies.

Authors:  Maria Carrillo; Lesley A Ricci; Glen A Coppersmith; Richard H Melloni
Journal:  Psychopharmacology (Berl)       Date:  2009-04-30       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.